The Chemo Pharma Laboratories - 2026 Company Profile, Team

About The Chemo Pharma Laboratories

The Chemo Pharma Laboratories is a publicly listed company based in Mumbai (India) founded in 1942. Bulk drugs and pharmaceuticals have been developed since 1942. Its chief executive, as recorded, is Shanta Somani. Its Indian entity Starsource Multitrade Limited reported revenue of ₹62 Lakh. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

The Chemo Pharma Laboratories was founded in 1942 in Mumbai, India, within the pharmaceutical sector. Operations have centered on manufacturing pharmaceuticals, with diversification into bulk drug production. A temporary cessation of business occurred, followed by revival through internal cash resources. Future plans include expansion of bulk drug activities and additional diversification efforts. Leadership is provided by CEO Shanta Somani.

Headquarters Mumbai, India
Stage Public
Sectors
Healthcare
Email
••••••••
Phone
•••• ••••
Website thechemopharmalaboratoriesltd.com
Social LinkedIn
Legal Name Starsource Multitrade Limited

Operational Areas

Healthcare → Biopharma Outsourcing & Drug Delivery

Key Metrics

Market Cap
₹17.10 Cr
STARSOURCE · BSE
Share Price
₹108.30
-5.00% today
EBITDA
−₹1.84 Cr
FY 2015-16
Net Profit
₹0.11 Cr
FY 2015-16
P/E (TTM)
54.4x
P/B 1.7x

Associated legal entities of The Chemo Pharma Laboratories

The Chemo Pharma Laboratories is associated with 2 registered companies on The Company Check; the primary company is Starsource Multitrade Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.

Legal entity	Status	Incorporated	Registered in	Revenue (FY 2025)	Employees	Directors	Company page
Starsource Multitrade Limited Listed CIN L46900MH1942PLC003556	Active	17 Aug 1942	Kalyan, Maharashtra	₹0.6 Cr		5	View details
Chemo Pharma Laboratories Ltd CIN L99999MH1942PLC003556		17 Aug 1942	Kalyan, Maharashtra, India				View details

Board of directors of Starsource Multitrade Limited (The Chemo Pharma Laboratories)

Starsource Multitrade Limited is the primary company behind The Chemo Pharma Laboratories. The board of Starsource Multitrade Limited currently have 5 directors; the longest-serving is Simiran Ankleshwar Tripathi, appointed in 2024. 16 earlier directors have ceased.

Director	Designation	Appointed	Tenure	Entity
Simiran Ankleshwar Tripathi DIN 10719879	Director	31 Dec 2024	1 yr 9 mo	Starsource Multitrade Limited
Ruchit Mehta DIN 08810586	Director	01 Apr 2025	1 yr 6 mo	Starsource Multitrade Limited
Sarvagya Goel DIN 10622443	Director	01 Apr 2025	1 yr 6 mo	Starsource Multitrade Limited
Shilpy Chopra DIN 07161915	Director	01 Apr 2025	1 yr 6 mo	Starsource Multitrade Limited
Utsav Trivedi DIN 10720143	Director	01 Apr 2025	1 yr 6 mo	Starsource Multitrade Limited

People of The Chemo Pharma Laboratories

1 people are tracked at The Chemo Pharma Laboratories (1 in leadership).

Name	Role	Group
Shanta Somani	CEO	Leadership

Premium access

Complete people profiles for The Chemo Pharma Laboratories

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

Full employee list
Team structure
Board tenure
Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of The Chemo Pharma Laboratories

The Chemo Pharma Laboratories is a publicly listed company on the BSE with ticker symbol STARSOURCE in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

IPO date10 Oct 2011
Listed onBSE: 506365
Listed entityStarsource Multitrade Limited
Exchange sectorHealth technology
ISININE320M01019
Share price₹107.46 (+2.34% on the day) · 2026-10-14
Volume (last session)859

Financials of The Chemo Pharma Laboratories

Exchange-reported figures of Starsource Multitrade Limited, the listed company behind The Chemo Pharma Laboratories (BSE: STARSOURCE).

Financial Highlights

FY 2015-16 · Consolidated

Revenue

₹0.00 Cr

EBITDA

−₹1.84 Cr

Profit After Tax

₹0.11 Cr

Net Worth

₹3.67 Cr

Total Assets

₹3.79 Cr

Total Debt

Nil

Financial summary ₹ Cr

Metrics	FY 2015-16
Income statement
Revenue	0.00
EBITDA	(1.84)
Profit before tax	(1.35)
Net profit	0.11
EPS (₹)	0.00
Balance sheet
Total assets	3.79
Net worth	3.67
Total debt	0.00
Cash & bank	0.44
Net working capital	2.12
Cash flow
Cash from operations	(2.09)
Cash from investing	2.15
Cash from financing	0.00

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Income statement
Revenue	0.53	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	(11.87)	(0.11)	(0.18)	(0.20)	(0.40)	(0.33)	(0.49)
EBITDA margin	-2239.6%	-	-	-	-	-	-
Profit before tax	(11.85)	0.50	1.65	0.08	0.37	0.32	0.49
Net profit	0.02	0.45	1.19	0.05	0.39	0.26	0.41
Net profit margin	+3.8%	-	-	-	-	-	-
EPS (₹)	(79.03)	2.28	8.00	0.32	3.73	1.67	2.77
Balance sheet
Total assets	1.30	13.14	12.80	11.60	11.55	10.99	10.74
Net worth	1.29	13.14	12.80	11.60	11.55	10.99	10.74
Total debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash & bank	0.01	10.62	6.11	6.06	6.19	10.87	8.81
Net working capital	1.28	10.60	6.06	6.11	6.19	10.90	8.69
Cash flow
Cash from operations	(10.62)	(0.28)	0.72	(0.68)	(0.33)	(0.41)	4.83
Cash from investing	0.01	10.46	(0.52)	0.63	0.97	(0.19)	1.01
Cash from financing	0.00	(0.16)	(0.15)	(0.08)	(2.12)	1.96	0.00

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	0.07	0.00	0.00	0.53	0.00	0.00	0.00	0.00
Other income	0.00	0.00	0.00	0.00	0.02	(0.16)	(0.15)	0.63
Total expenses	0.05	0.07	0.09	0.43	11.83	0.02	0.02	0.02
EBITDA	0.02	(0.07)	(0.09)	0.10	(11.83)	(0.02)	(0.02)	(0.02)
EBITDA margin	+28.6%	-	-	+18.9%	-	-	-	-
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit before tax	0.02	(0.07)	(0.09)	0.10	(11.81)	(0.18)	(0.17)	0.61
Tax	0.00	0.00	0.00	0.00	0.00	0.16	0.00	0.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026

Particulars	FY 2015-16
Revenue	0.00
Other income	0.49
Total expenses	1.84
Employee cost	0.03
EBITDA	(1.84)
Depreciation	0.00
Interest	0.00
Profit before tax	(1.35)
Tax	0.10
Net profit	0.11
EPS (₹)	0.00

Particulars	FY 2015-16
Equity & liabilities
Share capital	1.50
Reserves & surplus	2.17
Shareholders' funds (net worth)	3.67
Minority interest	0.00
Secured loans	0.00
Unsecured loans	0.00
Total debt	0.00
Total liabilities	3.79
Assets
Gross block	0.09
Net block	0.01
Capital work in progress	0.00
Investments	0.02
Inventories	0.00
Sundry debtors	0.00
Cash & bank balances	0.44
Loans & advances	1.75
Total current assets	2.19
Total current liabilities	0.07
Net working capital	2.12
Total assets	3.79

Particulars	FY 2015-16
Opening cash	0.38
Net cash from operating activities	(2.09)
Net cash from investing activities	2.15
Net cash from financing activities	0.00
Net change in cash	0.06
Closing cash	0.44

Particulars	FY 2015-16
Growth
PBT growth	+9997.0%
Profitability & leverage
Return on capital employed	0.0%
Return on net worth	0.0%
Debt / equity	0.00
Long-term debt / equity	0.00
Interest cover	0.00
Efficiency & per share
Fixed asset turnover	0.00
Inventory turnover	0.00
Debtors turnover	0.00
EPS (₹)	0.00
Dividend per share (₹)	0.00
Book value per share (₹)	24.49

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	0.07	0.00	0.00	0.53	0.00	0.00	0.00	0.00
Other income	0.00	0.00	0.00	0.00	0.02	(0.16)	(0.15)	0.63
Total expenses	0.05	0.07	0.09	0.43	11.83	0.02	0.02	0.02
EBITDA	0.02	(0.07)	(0.09)	0.10	(11.83)	(0.02)	(0.02)	(0.02)
EBITDA margin	+28.6%	-	-	+18.9%	-	-	-	-
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit before tax	0.02	(0.07)	(0.09)	0.10	(11.81)	(0.18)	(0.17)	0.61
Tax	0.00	0.00	0.00	0.00	0.00	0.16	0.00	0.00

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	0.53	0.00	0.00	0.00	0.00	0.00	0.00
Other income	0.02	0.62	1.84	0.30	0.79	0.67	1.00
Total expenses	12.40	0.11	0.18	0.20	0.40	0.33	0.49
Employee cost	0.09	0.02	0.02	0.07	0.14	0.09	0.15
EBITDA	(11.87)	(0.11)	(0.18)	(0.20)	(0.40)	(0.33)	(0.49)
EBITDA margin	-2239.6%	-	-	-	-	-	-
Depreciation	0.00	0.01	0.01	0.01	0.02	0.02	0.02
Interest	0.00	0.00	0.00	0.01	0.00	0.00	0.00
Profit before tax	(11.85)	0.50	1.65	0.08	0.37	0.32	0.49
Tax	0.00	0.16	0.44	0.03	(0.20)	0.06	0.08
Net profit	0.02	0.45	1.19	0.05	0.39	0.26	0.41
Net profit margin	+3.8%	-	-	-	-	-	-
EPS (₹)	(79.03)	2.28	8.00	0.32	3.73	1.67	2.77

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity & liabilities
Share capital	1.50	1.50	1.50	1.50	1.50	1.50	1.50
Reserves & surplus	(0.21)	11.64	11.30	10.10	10.05	9.49	9.24
Shareholders' funds (net worth)	1.29	13.14	12.80	11.60	11.55	10.99	10.74
Secured loans	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Unsecured loans	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total liabilities	1.30	13.14	12.80	11.60	11.55	10.99	10.74
Assets
Gross block	0.02	0.11	0.11	0.11	0.11	0.11	0.11
Net block	0.00	0.01	0.01	0.02	0.04	0.05	0.08
Capital work in progress	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.01	0.01	4.40	3.03	2.94	0.04	0.02
Inventories	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sundry debtors	0.49	0.00	0.00	0.00	0.00	0.00	0.00
Cash & bank balances	0.01	10.62	6.11	6.06	6.19	10.87	8.81
Loans & advances	1.30	0.19	0.14	0.07	0.11	0.09	0.10
Total current assets	1.80	10.81	6.25	6.13	6.30	10.96	8.91
Total current liabilities	0.52	0.21	0.19	0.02	0.11	0.06	0.22
Net working capital	1.28	10.60	6.06	6.11	6.19	10.90	8.69
Total assets	1.30	13.14	12.80	11.60	11.55	10.99	10.74

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Opening cash	10.62	0.61	0.56	0.69	2.17	0.81	2.97
Net cash from operating activities	(10.62)	(0.28)	0.72	(0.68)	(0.33)	(0.41)	4.83
Net cash from investing activities	0.01	10.46	(0.52)	0.63	0.97	(0.19)	1.01
Net cash from financing activities	0.00	(0.16)	(0.15)	(0.08)	(2.12)	1.96	0.00
Net change in cash	(10.61)	10.02	0.05	(0.13)	(1.49)	1.36	5.84
Closing cash	0.01	10.62	6.11	6.06	6.19	10.87	8.81

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Growth
EBITDA growth	-	+38.9%	+10.0%	+50.0%	-21.2%	+32.7%	-
PBT growth	-	-69.7%	+1962.5%	-78.4%	+15.6%	-34.7%	+88.5%
Net income growth	-95.6%	-62.2%	+2280.0%	-87.2%	+50.0%	-36.6%	-
EBITDA CAGR (3Y)	+290.1%	-35.0%	-18.3%	-25.8%	-10.6%	-1.0%	+22.0%
Profitability & leverage
Net income margin	-2235.9%	-	-	-	-	-	-
Return on capital employed	0.0%	+5.2%	+13.4%	+0.8%	+1.3%	+2.9%	+4.8%
Return on net worth	0.0%	+3.5%	+9.8%	+0.4%	+3.4%	+2.3%	+4.0%
Debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-term debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest cover	0.00	0.00	0.00	-4.76	0.00	0.00	0.00
Efficiency & per share
Fixed asset turnover	8.15	0.00	0.00	0.00	0.00	0.00	0.00
Inventory turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debtors turnover	2.16	0.00	0.00	0.00	0.00	0.00	0.00
EPS (₹)	(79.03)	2.28	8.00	0.32	3.73	1.67	2.77
Dividend per share (₹)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Book value per share (₹)	8.60	87.63	85.35	77.35	77.03	73.30	71.63

Similar companies to The Chemo Pharma Laboratories

The Chemo Pharma Laboratories has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company Name	Domain	Founded	HQ Location	Total funding	Employees	Description
Laurus Labs	lauruslabs.com	2005	Hyderabad, India	$229.73M	6,035	Pharmaceutical and biotechnology company
Symbiotec	symbiotec.in	2002	Indore, India	$61.01M	1,822	Non-sterile steroid hormone-based APIs and intermediates are manufactured.
SeQuent	sequent.in	2002	Bengaluru, India			APIs are developed and manufactured for therapeutic areas.

Premium access

Detailed similar companies of The Chemo Pharma Laboratories

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

Full competitor set
Operating metrics
Benchmarks
Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as The Chemo Pharma Laboratories (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

Company	Description	Founded	Location	Total funding	Revenue	Employees
Anthem Biosciences	Developer of integrated contract research development and manufacturing services	2007	Bengaluru, Karnataka, India	USD 35.74 M	USD 226.38 M	1,820
Laurus Labs	Pharmaceutical and biotechnology company	2005	Hyderabad, Telangana, India	USD 229.73 M	USD 726.15 M	12,470
Entero Healthcare	India's leading healthcare products distribution platform	2018	Mumbai, Maharashtra, India	USD 59.67 M	USD 702.49 M	4,260

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.

Included in your Premium account

✓
Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
✓
Full access to every database India & global coverage, advanced filters and rich profile details
✓
Always-on access from your team account Single premium plan for everything you see on the portal

Related news about The Chemo Pharma Laboratories

Starsource Multitrade reports standalone net profit of Rs 0.02 crore in the June 2026 quarter | Capital Market News - Business Standard

Business Standard • 2 months ago

STARSOURCE: Q1 FY27 saw a return to profit with ₹209.84 thousand PAT and auditor's GST-related qualification

Quartr • 2 months ago

STARSOURCE: FY26 saw a steep net loss, asset erosion, and audit concerns over sales reporting

Quartr • 4 months ago

STARSOURCE: Reported a net loss of ₹118.55 million, with major management changes and new business focus

Quartr • 4 months ago

STARSOURCE: No revenue and a net loss of ₹865.11 thousand reported for the quarter ended Dec 31, 2025

Quartr • 8 months ago

STARSOURCE: Q2 FY26 returned to profit with revenue growth, but assets and cash fell significantly

Quartr • 11 months ago

STARSOURCE: Q1 FY26 saw a steep net loss and no revenue as the company prepares for a major business shift

Quartr • 1 year ago

STARSOURCE: Net loss and revenue drop in FY25, but liquidity remains strong; audit unmodified

Quartr • 1 year ago

STARSOURCE: Profit and revenue fell sharply; company pivots to trading, boosts cash, and changes management

Quartr • 1 year ago

STARSOURCE: Quarterly net loss driven by negative revenue and higher expenses, with notable tax adjustments

Quartr • 1 year ago

Premium access

Complete news archive for The Chemo Pharma Laboratories

Full article history, source details, and older brand coverage require an active premium plan.

Full article archive
Source and publication date
Older coverage
Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about The Chemo Pharma Laboratories

When was The Chemo Pharma Laboratories founded?

The Chemo Pharma Laboratories was founded in 1942.

Where is The Chemo Pharma Laboratories located?

The Chemo Pharma Laboratories is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Who is the CEO of The Chemo Pharma Laboratories?

Shanta Somani is the CEO of The Chemo Pharma Laboratories, as recorded in our data.

What is the annual revenue of The Chemo Pharma Laboratories?

The primary company behind The Chemo Pharma Laboratories, Starsource Multitrade Limited, reported revenue of ₹62 Lakh for FY 2025, down 66% year on year.

What does The Chemo Pharma Laboratories do?

The Chemo Pharma Laboratories was founded in 1942 in Mumbai, India, within the pharmaceutical sector. Operations have centered on manufacturing pharmaceuticals, with diversification into bulk drug production. A temporary cessation of business occurred, followed by revival through internal cash resources. Future plans include expansion of bulk drug activities and additional diversification efforts. Leadership is provided by CEO Shanta Somani.

Which companies are similar to The Chemo Pharma Laboratories?

The Chemo Pharma Laboratories's top competitors include Laurus Labs, Symbiotec and SeQuent.

Is The Chemo Pharma Laboratories publicly traded?

Yes, The Chemo Pharma Laboratories is publicly traded on BSE under the ticker symbol STARSOURCE.

Which legal entities are associated with The Chemo Pharma Laboratories?

The Chemo Pharma Laboratories operates through Starsource Multitrade Limited.

Who are the directors of The Chemo Pharma Laboratories?

The legal entities of The Chemo Pharma Laboratories currently have 5 directors, including Ruchit Mehta, Sarvagya Goel, Shilpy Chopra and others.

About The Chemo Pharma Laboratories

Company details

Operational Areas of The Chemo Pharma Laboratories

Associated legal entities of The Chemo Pharma Laboratories

Board of directors of Starsource Multitrade Limited (The Chemo Pharma Laboratories)

People of The Chemo Pharma Laboratories

Complete people profiles for The Chemo Pharma Laboratories

IPO & Listings of The Chemo Pharma Laboratories

Financials of The Chemo Pharma Laboratories

Financial Highlights

Financial summary ₹ Cr Consolidated Standalone AnnualQuarterly

Financial Statements

Similar companies to The Chemo Pharma Laboratories

Detailed similar companies of The Chemo Pharma Laboratories

Top companies in Biopharma Outsourcing & Drug Delivery

Related news about The Chemo Pharma Laboratories

Complete news archive for The Chemo Pharma Laboratories

Frequently Asked Questions about The Chemo Pharma Laboratories

Financial summary ₹ Cr